Table 3 Mitochondrial transplantation therapy clinical trials for CNS disorders
From: Mitochondrion-based organellar therapies for central nervous system diseases
Disease | Status | NCT number | Phase | Mitochondria transplantation and donor | Number of recruits | Start time and expected completion time (completed time) | Organization | Articles published |
|---|---|---|---|---|---|---|---|---|
Pearson Syndrome | Completed | NCT03384420 | Â | Autologous stem cell transplantation enriched with MNV-BLD (blood-derived mitochondria) | 7 | 2019.02.13 2021.03.09 | Sheba Medical Center Hospital- Tel Hashomer Ramat Gan, Israel | [221] |
Stroke | Recruiting | NCT04998357 | Phase 1 | Intravascular autologous mitochondrial transfer | 20 | 2021.08.10 2024.04.29 | Harborview Medical Center Seattle, Washington, United States | Â |
Refractory polymyositis or dermatomyositis | Enrolling by invitation | NCT04976140 | Phase 1 & 2 | Allogeneic mitochondria isolated from allogeneic umbilical cord-derived MSCs were injected intravenously | 18 | 2021.07.26 2023.04 | Seoul National University Hospital Seoul, Korea, Republic of | Â |